• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    World No. 1 Tennis Star Aryna Sabalenka Joins Prenetics' IM8 Health as Global Ambassador and Shareholder

    6/26/25 4:30:00 AM ET
    $PRE
    Blank Checks
    Finance
    Get the next $PRE alert in real time by email
    • Aryna Sabalenka becomes first-ever current athlete shareholder in Prenetics, listed on the NASDAQ: (PRE)



    • In just six months, IM8 is one of the fastest growing supplement brands in the world, generating an extraordinary US$50m+ Annual Recurring Revenue



    • IM8 has built a loyal customer base of 60,000+ users who have consumed over 5 million servings



    • IM8, co-founded by David Beckham is available at www.im8health.com

    CHARLOTTE, N.C., June 26, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE), a leading consumer health sciences company, announced today at a special event at Wimbledon House that IM8, its premium supplements brand co-founded by David Beckham, has partnered with world No. 1 tennis star Aryna Sabalenka as its newest global ambassador and shareholder. The announcement comes just days before the start of Wimbledon on June 30th, where Sabalenka will be competing as one of the tournament favorites.

    Prenetics Global Limited

    The partnership marks a significant milestone for both Sabalenka and IM8, as this represents the first time the tennis champion has endorsed a supplement brand. The collaboration was born organically after Sabalenka experienced remarkable benefits from using IM8's Daily Ultimate Essentials, which is NSF Certified for Sport®, since the beginning of 2025.

    Sabalenka, who is preparing for Wimbledon after an impressive first half of 2025 that saw her claim three prestigious titles in Brisbane, Miami, and Madrid, has reported significant improvements in energy, endurance, digestion, and cognitive focus since incorporating IM8 into her daily routine. Her entire team, including her tennis coaches and personal trainer, have also become regular users of the product.

    "As a professional athlete, I'm extremely cautious about what I put in my body. I've tried countless supplements and naturally am always skeptical. Trust is everything," said Sabalenka. "After my coach recommended IM8, I noticed a difference within weeks – better energy throughout long matches, faster recovery, and improved focus when it matters most. What truly won me over was their deep scientific advisory board with experts from Mayo Clinic and other leading institutions, combined with the fact that IM8 is NSF Certified for Sport®. This gives me absolute confidence in its purity, quality, and scientific foundation. This partnership goes far beyond a typical endorsement – I've become a shareholder in Prenetics because I genuinely believe in what this product delivers. Being part of a brand co-founded by David Beckham, who understands the demands of elite sports at the highest level, makes this even more special. The results I've experienced firsthand have transformed my approach to optimal nutrition."

    Sabalenka added, "While being constantly on the road, it's incredibly valuable knowing that IM8 can replace 16 supplements with clinical dosages– it's simplified my nutrition regimen while ensuring I get everything I need. It's become an essential part of my daily routine and my entire team's regimen as well. I'm truly excited about the entire IM8 team and what they're building – their commitment to quality and innovation in supplements is something I wanted to be part of beyond just being an ambassador."

    "I'm absolutely thrilled to welcome Aryna to the IM8 family – not just as our global ambassador, but as a shareholder who truly believes in what we're building," said Danny Yeung, CEO of Prenetics, the parent company of IM8. "What makes this partnership extraordinary is that Aryna's journey with IM8 began organically through her performance coach, experiencing the benefits firsthand as a genuine customer before we ever discussed an official relationship. Aryna represents the pinnacle of athletic excellence, mental strength, and professionalism – qualities that perfectly align with our brand values. When an athlete of her caliber not only uses the product but also invests in the company, it speaks volumes about the quality and efficacy of what we've created. Her authentic experience and passionate advocacy for IM8 reinforces our mission to provide premium, science-backed supplements that deliver real results for everyone from elite athletes to everyday health enthusiasts."

    The partnership comes at a time when supplement safety and quality are increasingly important topics in professional tennis. Recent high-profile cases have highlighted the risks athletes face with contaminated supplements, making IM8's NSF Certified for Sport® designation particularly significant. This certification ensures that products are regularly tested for more than 280 substances prohibited in sport and confirms that they contain the ingredients listed on the label without unsafe levels of contaminants.

    Since its launch in December 2024, IM8 has experienced extraordinary growth, achieving US$50m+ Annual Recurring Revenue and serving more than 60,000 customers and delivering over 5 million servings of its premium supplements. This remarkable trajectory places IM8 among the fastest growing supplement brands globally. Industry analysts have noted that IM8's revenue velocity in its first six months exceeds typical benchmarks for successful supplement launches by 500%.

    The special announcement event at Wimbledon House featured Sabalenka alongside Prenetics executives, IM8's Scientific Advisory Board members, including Dr. Dawn Mussallem from Mayo Clinic and Dr. Ara Suppiah, Functional Sports Physician, as well as media, and friends of the brand. The gathering highlighted the significance of this partnership as Sabalenka prepares for one of tennis's most prestigious tournaments.

    IM8's Daily Ultimate Essentials are available at www.im8health.com.

    Press Kit: HERE

    About Prenetics

    Prenetics (NASDAQ:PRE), a leading health sciences company, is dedicated to advancing consumer health. Our consumer initiative is led by IM8, a fast-growing health and wellness brand, Europa, one of the largest sports distribution companies in the USA, and CircleDNA, a leading direct-to-consumer DNA test. As the first healthcare company to establish a Bitcoin treasury with its initial $20 million Bitcoin purchase and board-approved comprehensive Bitcoin strategy, Prenetics is pioneering the intersection of healthcare innovation and digital asset adoption. Each of Prenetics' units synergistically enhances our global impact on health, embodying our commitment to "enhancing life through science". To learn more please visit prenetics.com and IM8health.com

    About IM8

    IM8 is the pinnacle of premium core nutrition, born from a collaboration between David Beckham as a co-founding partner, and an elite team of scientists spanning medical professionals, academia and space science. Combining cutting-edge science with nature's most potent ingredients, IM8 delivers a holistic, science-backed approach to health, empowering you to live your most vibrant life. IM8's flagship product, Daily Ultimate Essentials is an all-in-one powder supplement engineered to replace 16 different supplements in a delicious drink and is NSF Certified for Sport, non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors or sweeteners. IM8 is a 100% owned subsidiary of Prenetics (NASDAQ:PRE), a leading global health sciences company dedicated to advancing consumer health.

    About Aryna Sabalenka

    Aryna Sabalenka is the current world No. 1 tennis player and one of the sport's most dominant forces. In 2025 alone, she has claimed three prestigious titles in Brisbane, Miami, and Madrid, continuing her impressive career trajectory. Known for her powerful playing style and mental fortitude, Sabalenka has established herself as one of tennis's premier athletes.

    Media Contact:

    Angela Cheung

    Investor Relations / Corporate Finance

    Prenetics Global Limited

    [email protected]



    Danielle Mulholland

    Jack Taylor Public Relations

    [email protected]

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7953550c-a837-48d1-be27-1a4ea59ba94c



    Primary Logo

    Get the next $PRE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRE

    DatePrice TargetRatingAnalyst
    2/11/2026$36.00Buy
    Roth Capital
    1/18/2023$7.00Overweight
    Cantor Fitzgerald
    7/12/2022Buy
    Citigroup
    More analyst ratings

    $PRE
    SEC Filings

    View All

    SEC Form 6-K filed by Prenetics Global Limited

    6-K - Prenetics Global Ltd (0001876431) (Filer)

    3/6/26 8:07:42 AM ET
    $PRE
    Blank Checks
    Finance

    SEC Form 6-K filed by Prenetics Global Limited

    6-K - Prenetics Global Ltd (0001876431) (Filer)

    3/3/26 8:47:27 AM ET
    $PRE
    Blank Checks
    Finance

    SEC Form 6-K filed by Prenetics Global Limited

    6-K - Prenetics Global Ltd (0001876431) (Filer)

    2/18/26 9:28:49 AM ET
    $PRE
    Blank Checks
    Finance

    $PRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on Prenetics Group Ltd. with a new price target

    Roth Capital initiated coverage of Prenetics Group Ltd. with a rating of Buy and set a new price target of $36.00

    2/11/26 7:52:37 AM ET
    $PRE
    Blank Checks
    Finance

    Cantor Fitzgerald initiated coverage on Prenetics Group Ltd. with a new price target

    Cantor Fitzgerald initiated coverage of Prenetics Group Ltd. with a rating of Overweight and set a new price target of $7.00

    1/18/23 7:56:45 AM ET
    $PRE
    Blank Checks
    Finance

    Citigroup initiated coverage on Prenetics Group Ltd.

    Citigroup initiated coverage of Prenetics Group Ltd. with a rating of Buy

    7/12/22 11:48:35 AM ET
    $PRE
    Blank Checks
    Finance

    $PRE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Prenetics Authorizes $40 Million Share Repurchase Program

    Management and Board Have Collectively Committed Up to $42.75 Million to Prenetics Stock Backed by $164 Million in Total Adjusted Liquidity, Zero Debt IM8 Targeting $180M to $200M in 2026 Full Year Revenue, and a Clear Path to Adjusted EBITDA Profitability by Q4 2027 NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium health and longevity brand, today announced that its Board of Directors (the "Board") has authorized a share repurchase program of up to $40,000,000 over a 12-month period. Management Voted With Its Own Capital First During the week of Feb

    3/6/26 8:00:00 AM ET
    $PRE
    Blank Checks
    Finance

    Prenetics Executives Execute Second Consecutive Round of Post-Earnings Open Market Share Purchases of $1.3 Million— Cumulative Personal Investment Across Both Rounds Reaches $2.7 Million

    -  CEO Danny Yeung makes personal investment in this round of approximately $750,000, up from investment of approximately $502,000 in November 2025 NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium health and longevity brand, today announced that members of its executive leadership team have executed a second round of open market purchases of Prenetics common stock during the week of February 23 to 27, 2026, within the Company's open trading window following the release of its financial results for the fourth quarter and full year 2025. This is the sec

    3/3/26 8:00:00 AM ET
    $PRE
    Blank Checks
    Finance

    Prenetics Launches IM8 Daily Ultimate Essentials PRO — A Clinical Formula with Two New Flavours

    Up to 733% Greater Potency Across 11 Key Nutrients, Including New Saffron Nootropic and Bioactive Vitamin Forms Two New Flavours — Mango + Passionfruit and Lemon + Orange Same Price for New and Existing Customers Full Supplement Facts Available at im8health.com/products/essentials NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced the launch of Daily Ultimate Essentials PRO, a new clinical-grade version of its flagship daily health supplement under the IM8 Health brand. Alongside the reformulated product, Pren

    2/23/26 9:00:00 AM ET
    $PRE
    Blank Checks
    Finance

    $PRE
    Leadership Updates

    Live Leadership Updates

    View All

    Formula 1 Phenom Ollie Bearman Joins Prenetics' IM8 Health as Global Ambassador and Shareholder

    Ollie Bearman becomes the latest elite athlete to invest in NASDAQ:PRE, underscoring a deep belief in the brand's mission and products.IM8, co-founded by David Beckham, continues to attract top-tier athletes who prioritize scientifically validated and trusted nutritional support.IM8 has become one of the fastest-growing supplement brands globally, achieving an extraordinary US$100 million in Annual Recurring Revenue in just 11 months from launch.Bearman's rapid rise – including a historic points-scoring Ferrari debut at just 18—cements his reputation as one of motorsport's brightest young talents. NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE), a leading

    2/13/26 8:00:00 AM ET
    $PRE
    Blank Checks
    Finance

    Prenetics Becomes First Healthcare Company to Execute Aggressive Bitcoin Treasury Strategy, Secures $20M in BTC, Appoints Former OKEx COO to Board

    -  Prenetics adopts proven corporate Bitcoin strategy inspired by MicroStrategy's ~$40B Bitcoin holdings and Metaplanet's meteoric treasury transformation -  Following strategic divestiture, Prenetics leverages strengthened $117M balance sheet to execute comprehensive Bitcoin strategy with board-approved majority allocation, institutional financing partnerships, and alpha-generating initiatives. CHARLOTTE, N.C., June 18, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE), a leading health sciences company, today announced it has become the first healthcare company to establish a Bitcoin treasury, completing a $20 million Bitcoin purchase of 187.42 BTC at an averag

    6/18/25 8:45:00 AM ET
    $PRE
    Blank Checks
    Finance

    Prenetics Welcomes Kathyrn M. Henry and David Vanderveen to Board of Directors

    LOS ANGELES, July 01, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, welcomes Kathryn M. Henry and David Vanderveen as independent directors to the Company's Board of Directors. "We are excited to welcome Kathryn and David to Prenetics' Board of Directors at this pivotal juncture," said Danny Yeung, CEO of Prenetics. "Their unparalleled expertise in consumer and health sectors, combined with their proven leadership in driving global expansion and operational excellence, will significantly enhance shareholder value as we expand into consumer health and wellness." "I am thrilled to join Prenetics at such a p

    7/1/24 8:30:00 AM ET
    $PRE
    Blank Checks
    Finance

    $PRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Prenetics Global Limited

    SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

    11/14/24 12:30:15 PM ET
    $PRE
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by Prenetics Global Limited (Amendment)

    SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

    2/5/24 6:05:14 AM ET
    $PRE
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by Prenetics Global Limited (Amendment)

    SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

    11/27/23 6:05:43 AM ET
    $PRE
    Blank Checks
    Finance

    $PRE
    Financials

    Live finance-specific insights

    View All

    Prenetics Reports Record Q4 and FY 2025 Results: IM8 Achieves $120M ARR¹ in 12 Months, Revenue Surges 480% YoY

    Total Revenue Increased 480% to $92.4 million for Full Year 2025, Q4 Revenue reached $36.6 millionIM8 Reaches $10 Million in Monthly Revenue in December 2025, Achieving $120M ARR MilestoneStrategic Transformation Completed with Divestitures and Focus on IM8 Total Adjusted Liquidity2 of Approximately $171 Million Following Sale of Insighta Stake to Tencent, with Zero DebtCompany to Host Earnings Call on February 18, 2026, at 10:00 a.m. ET and latest investor deck can be found at https://ir.prenetics.com NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium he

    2/18/26 9:11:26 AM ET
    $PRE
    Blank Checks
    Finance

    Prenetics to Report Q4 and Full Year 2025 Financial Results on Feb 18, 2026 and Host Earnings Conference Call

    NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced it will release financial results for the fourth quarter and full year 2025 ended December 31, 2025 before market open on Wednesday, February 18, 2026. The Company will also hold its earnings conference call the same day at 10:00 a.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with analysts. Date:Wednesday, February 18, 2026Time:10:00 a.m. Eastern TimeDial-in:1-877-425-9470International Dial-in:1-201-389-0878

    2/11/26 8:00:00 AM ET
    $PRE
    Blank Checks
    Finance

    Prenetics Reports Record Third Quarter 2025 Results; IM8 on Track for $120M ARR¹ by December 2025, Fastest Supplement Brand Growth in Industry History

    Total Revenue Surges 568% YoY to $23.6 million; IM8 Monthly Revenue Hits Record US$9 million in October; Bitcoin Treasury Reaches 387 BTC (~$40M); IM8 Projects $180 - $200M FY 2026 Revenue, $25M Monthly Revenue or $300M ARR by Year End 2026 IM8 Delivers 60% Gross Margin, 3.9 Months Payback Period, Demonstrating Strong Unit Economics Company to Host Earnings Call Today at 8:30am ET, Releases Inaugural Quarterly Shareholder Letter CHARLOTTE, N.C., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced third quarter 2025 financial

    11/10/25 7:24:27 AM ET
    $EXOD
    $PRE
    Finance: Consumer Services
    Finance
    Blank Checks